Jing Rong Cui
Fundador en Blossomhill Therapeutics, Inc. .
Perfil
Jing Rong Cui is the founder of Turning Point Therapeutics, Inc. which was founded in 2013.
She held the title of Director in the company in 2020.
Dr. Cui is also the founder of Blossomhill Therapeutics, Inc. Dr. Cui earned a doctorate degree from The Ohio State University and undergraduate and graduate degrees from the University of Science & Technology of China.
Cargos activos de Jing Rong Cui
| Empresas | Cargo | Inicio |
|---|---|---|
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Fundador | - |
Antiguos cargos conocidos de Jing Rong Cui.
| Empresas | Cargo | Fin |
|---|---|---|
| TURG POIN | Fundador | 15/06/2020 |
Formación de Jing Rong Cui.
| The Ohio State University | Doctorate Degree |
| University of Science & Technology of China | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Jing Rong Cui
